title: Adjunctive use of ezogabine/retigabine with either traditional sodium channel blocking antiepileptic drugs (AEDs) or AEDs with other mechanisms of action: Evaluation of efficacy and tolerability.
abstract: Integrated data from three double-blind, randomized, placebo-controlled trials were analyzed to evaluate the efficacy and tolerability of ezogabine (EZG; US adopted name)/retigabine (RTG; international non-proprietary name) when used in combination with ≥1 sodium channel blocking antiepileptic drug (AED), ≥1 non-sodium channel blocking AED, or ≥1 AED from both the sodium channel and non-sodium channel mechanistic groups. Efficacy and tolerability appeared to be similar across all three groups of patients.
authors.affiliation: Epilepsy Unit, Western Infirmary, University of Glasgow, Glasgow, UK. Electronic address: Martin.Brodie@glasgow.ac.uk.
authors.forename: Martin J
authors.initials: MJ
authors.lastname: Brodie
authors.affiliation: Comprehensive Epilepsy Center, Department of Neurology, New York University, New York, NY, USA. Electronic address: Jacqueline.French@nyumc.org.
authors.forename: Jacqueline A
authors.initials: JA
authors.lastname: French
authors.affiliation: GlaxoSmithKline, Research Triangle Park, NC, USA. Electronic address: susan.a.mcdonald@gsk.com.
authors.forename: Susan A
authors.initials: SA
authors.lastname: McDonald
authors.affiliation: GlaxoSmithKline, Research Triangle Park, NC, USA. Electronic address: wen-jene.k.lee@gsk.com.
authors.forename: Wen-Jene
authors.initials: WJ
authors.lastname: Lee
authors.affiliation: GlaxoSmithKline, Research Triangle Park, NC, USA. Electronic address: bryan.e.adams@gsk.com.
authors.forename: Bryan
authors.initials: B
authors.lastname: Adams
authors.affiliation: Valeant Pharmaceuticals North America, Durham, NC, USA. Electronic address: andrew.scott@valeant.com.
authors.forename: Andrew
authors.initials: A
authors.lastname: Scott
authors.affiliation: Valeant Pharmaceuticals North America, Durham, NC, USA. Electronic address: vnohria@aol.com.
authors.forename: Virinder
authors.initials: V
authors.lastname: Nohria
authors.affiliation: GlaxoSmithKline, Research Triangle Park, NC, USA. Electronic address: sarah.e.derossett@gsk.com.
authors.forename: Sarah
authors.initials: S
authors.lastname: DeRossett
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002219:Carbamates / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D010655:Phenylenediamines / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D026941:Sodium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants; D002219:Carbamates; D010655:Phenylenediamines; D026941:Sodium Channel Blockers; C101866:ezogabine
keywords: Antiepileptic drugs; Efficacy; Ezogabine; Rational polytherapy; Retigabine; Tolerability